Cue Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shao-Lee Lin
- Full Time Employees
- 29
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 40 Guest Street Boston MA United States of America 02135
- IPO Date
- Jan 2, 2018
- CIK
- 0001645460
- Website
- cuebiopharma.com
- Similar Companies
- Business
- Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development of novel biologic therapeutics that selectively engage and modulate disease-relevant T cells to treat autoimmune diseases and cancers. Its core product portfolio includes engineered biologics based on its proprietary Immuno-STAT™ platform designed to mimic natural immune signals, with key candidates such as CUE-101 for HPV16+ head and neck squamous cell carcinoma, CUE-401 targeting autoimmune diseases, and CUE-501, a bispecific molecule for selective B cell depletion in autoimmune and inflammatory conditions. The company’s therapeutics aim to enhance immune system precision to improve clinical outcomes by targeting and altering specific immune cell subsets without broad systemic activation. Cue Biopharma operates primarily in the United States with a focus on the oncology and immunology segments. Recent major developments include a strategic collaboration and license agreement with ImmunoScape to develop novel cell therapy approaches for solid tumors, which involves significant upfront and milestone payments and a 40% equity stake for ImmunoScape. Cue Biopharma also entered a licensing deal with Boehringer Ingelheim entailing a $12 million upfront payment for the development of CUE-501 and potential expansion into other anti-B cell therapies for autoimmune diseases. Clinical advances include positive Phase 1 trial results for CUE-101 combined with pembrolizumab, demonstrating a 50% overall response rate and extended median overall survival in HPV+ head and neck cancer patients. The company raised $20 million in a public offering to strengthen its financial position and reported favorable FDA feedback on its planned clinical development of CUE-401. Leadership changes include the appointment of Usman Azam as CEO effective September 2025. Founded in 2015, Cue Biopharma continues to expand its pipeline and strategic partnerships to advance its novel immunotherapies for targeted immune modulation in disease treatment.
Company News
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
Cue Biopharma Announces $50.0 Million Private Placement
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma Announces $30 Million Private Placement
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma Announces 1-for-30 Reverse Stock Split
Cue Biopharma AGM: Shareholders Approve Reverse Stock Split, Elect Directors, Ratify Auditor
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim